Read Taconic's response to coronavirus (COVID-19), and visit our toolkit for researchers. Learn More
hIL-6 NOG Mouse Model

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 13686-F
    sp/sp;ko/ko;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)1-1Jic/JicTac
  • 13686-M
    sp/sp;ko/y;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)1-1Jic/JicTac
  • Super immunodeficient NOG mouse expressing human IL-6 cytokine
  • Enhanced expansion of human monocytes following human HSC engraftment
  • May be useful for study of tumor-infiltrating macrophages
  • May be suitable host for hIL-6 dependent multiple myeloma (MM) patient derived xenograft (PDX) and tumor samples.
  • Applications in research involving cancer, immunology, regenerative medicine and human immune system engraftment
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:

“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH

Origin:

The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The linearized hIL-6 transgene was injected into zygotes from NOD/Shi-IL2rg females x NOD/Shi-IL2rg males.  The transgenic hIL-6 NOD/Shi-IL2rg mouse was crossed on to the NOG background to introduce the Prkdc scid mutation.  The mice were backcrossed onto the NOG background three times.  Taconic received stock in 2014, and the line was derived through embryo transfer.

Availability:

Available now*
*Please note that advance order is encouraged for order of male mice. There is a minimal 4-week advance notice required on orders of male older than 3 weeks of age.

Color:

Albino

Species:

Mouse

Initial Publication:

Hanazawa A, Ito R, Katano I, Kawai K, Goto M, Suemizu H, Kawakami Y, Ito M, Takahashi T. (2018) Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. Front Immunol 9:152.


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Humanized hIL-6 NOG Mice Supports Human Monocytes/Macrophages & Immunosuppressive Human Tumor Microenvironment

Development of human monocytes/macrophages in hIL-6 NOG engrafted with human CD34+ stem cells

Development of human monocytes/macrophages in hIL-6 NOG engrafted with human CD34+ stem cells
Figure 1: (a) The frequency of CD33+CD14+ monocytes/macrophages in hCD45+ leukocytes, obtained by flow cytometry. (b) The absolute number of CD33+CD14+ monocytes/macrophages, calculated by multiplying the number of total MNCs by the frequencies of each human subpopulation determined by FACS. (c) The distributions of human macrophages in HSC-engrafted NOG and hIL-6 NOG mice, assessed in paraffin-embedded lung, liver, spleen, and BM. Adapted from Hanazawa, et al. 2018 under Creative Commons Attribution License.

Development of human tumor-associated macrophages (TAMs) in tumor-engrafted humanized hIL-6 NOG mice

Development of human tumor-associated macrophages (TAMs) in tumor-engrafted humanized hIL-6 NOG mice
Figure 2: (a) Schema of generation of tumor-bearing humanized mice. (b) Immunohistochemistry of human macrophages in tumor and spleen at 36-51 days after tumor transplantation. (c) Enumeration of CD68+ or CD163+ macrophages. (d) Expression of IL-4Rα in human macrophages. FACS plots of IL-4Rα in hCD45+CD14+CD68+ macrophages in tumor, spleen, and PB of HSC4-engrafted HSC-NOG-hIL-6 Tg (upper panels) and histogram of hIL-4Rα expression in hCD68+ macrophages in various tissues (bottom panel). Adapted from Hanazawa, et al. 2018 under Creative Commons Attribution License.